vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and CollPlant Biotechnologies Ltd (CLGN). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $179.0K, roughly 1010.6× CollPlant Biotechnologies Ltd). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -1869.8%, a 1869.1% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -28.1%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
AVNS vs CLGN — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $179.0K |
| Net Profit | $-1.3M | $-3.3M |
| Gross Margin | 47.5% | -3.9% |
| Operating Margin | 1.4% | -1775.4% |
| Net Margin | -0.7% | -1869.8% |
| Revenue YoY | 0.7% | -28.1% |
| Net Profit YoY | 99.7% | 20.5% |
| EPS (diluted) | $-0.02 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | — | ||
| Q3 25 | $177.8M | — | ||
| Q2 25 | $175.0M | $179.0K | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | — | ||
| Q3 24 | $170.4M | — | ||
| Q2 24 | $171.7M | $249.0K | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-76.8M | $-3.3M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $1.8M | $-4.2M | ||
| Q1 24 | $-900.0K | — |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | -3.9% | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | -115.3% | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | -1775.4% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | -1769.5% | ||
| Q1 24 | 2.4% | — |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | -43.9% | -1869.8% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.0% | -1690.8% | ||
| Q1 24 | -0.5% | — |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | $0.28 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | $0.37 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $11.4M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $12.5M |
| Total Assets | $1.1B | $17.4M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | $11.4M | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | $18.9M | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | — | ||
| Q3 25 | $778.0M | — | ||
| Q2 25 | $776.3M | $12.5M | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | $20.7M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | $17.4M | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | $26.6M | ||
| Q1 24 | $1.7B | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | — | ||
| Q2 25 | $6.8M | — | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | — | ||
| Q3 24 | $23.0M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CLGN
Segment breakdown not available.
